Patents Assigned to RNAimmune, Inc.
-
Patent number: 12280105Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from a delta variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.Type: GrantFiled: February 9, 2024Date of Patent: April 22, 2025Assignee: RNAIMMUNE, INC.Inventors: Neeti Ananthaswamy, Yong-Sik Bong, David Brown, Renxiang Chen, Ju Hyeong Jeon, Zhifeng Long, Dong Shen, Chun Lu, Patrick Y. Lu, Shenggao Tang, Jiaxi He, Ziyang He
-
Patent number: 12280104Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.Type: GrantFiled: October 31, 2023Date of Patent: April 22, 2025Assignee: RNAIMMUNE, INC.Inventors: David Brown, Yong-Sik Bong, Neeti Ananthaswamy, Naihsuan C. Guy, Dong Shen
-
Publication number: 20240374697Abstract: Compositions and methods are provided for potent mRNA vaccines for treatment of cancer with mutations in ras gene family multiplexed with TP53. The compositions include a pharmaceutical composition containing mRNA molecules encoding multiple peptides of a group of somatic mutations together with a pharmaceutically acceptable carrier. Methods for stimulating system immune responses and treatment are provided, including intratumoral, intravenous, intramuscular, intradermal, and subcutaneous injection.Type: ApplicationFiled: December 8, 2023Publication date: November 14, 2024Applicant: RNAimmune, Inc.Inventors: Dong SHEN, David BROWN
-
Publication number: 20240370011Abstract: Provided herein is a ribonucleic acid (RNA) encoding a fusion glycoprotein (F) protein or an immunogenic fragment thereof of a respiratory syncytial virus (RSV) comprising at least one non-naturally occurring amino acid mutation. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.Type: ApplicationFiled: July 23, 2024Publication date: November 7, 2024Applicant: RNAimmune, Inc.Inventors: David Brown, Neeti Ananthaswamy, Renxiang Chen
-
Publication number: 20240294580Abstract: Provided herein is a ribonucleic acid (RNA) encoding a fusion glycoprotein (F) protein or an immunogenic fragment thereof of a respiratory syncytial virus (RSV) comprising at least one non-naturally occurring amino acid mutation. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.Type: ApplicationFiled: May 16, 2024Publication date: September 5, 2024Applicant: RNAimmune, Inc.Inventors: David Brown, Neeti Ananthaswamy, Renxiang Chen
-
Publication number: 20240226275Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from a delta variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.Type: ApplicationFiled: February 9, 2024Publication date: July 11, 2024Applicant: RNAimmune, Inc.Inventors: Neeti Ananthaswamy, Yong-Sik Bong, David Brown, Renxiang Chen, Ju Hyeong Jeon, Zhifeng Long, Dong Shen, Chun Lu, Patrick Y. Lu, Shenggao Tang, Jiaxi He, Ziyang He
-
Patent number: 12029786Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.Type: GrantFiled: February 8, 2021Date of Patent: July 9, 2024Assignee: RNAimmune, Inc.Inventors: Shenggao Tang, Dong Shen, Chun Lu, Ziyang He, Jiaxi He, Patrick Y. Lu
-
Publication number: 20240156947Abstract: Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from an Omicron variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.Type: ApplicationFiled: October 31, 2023Publication date: May 16, 2024Applicant: RNAimmune, Inc.Inventors: David BROWN, Yong-sik BONG, Neeti ANANTHASWAMY, Naihsuan C. GUY, Dong SHEN
-
Publication number: 20230355527Abstract: Novel lipids, compositions, and methods of using the novel lipids and compositions are disclosed. Three-component lipid nanoparticle compositions comprising the novel lipids or other types of lipids, and methods of using the three-component lipid nanoparticle compositions are disclosed. Three-component lipid nanoparticle compositions contain a steroidal or structural lipid-containing component, a PEGylated lipid-containing component, a cationic or ionizable lipid-containing component, and are free of phospholipids. Pharmaceutical formulations including the three-component lipid nanoparticle compositions and further including therapeutic and/or prophylactics such as mRNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs.Type: ApplicationFiled: April 7, 2023Publication date: November 9, 2023Applicant: RNAimmune, Inc.Inventors: Evan Michael Lewoczko, Renxiang Chen, Neeti Ananthaswamy, Dong Shen
-
Publication number: 20230108926Abstract: Compositions and methods are provided for potent mRNA vaccines for prevention and treatment of 2019 novel Coronavirus (2019-nCoV) infections. The compositions include a pharmaceutical composition containing one or more mRNA molecules encoding spike protein epitopes, including mutated epitopes, or mRNA cocktails that encode critical viral genes together with pharmaceutically acceptable polymeric nanoparticle carriers and liposomal nanoparticle carriers. Methods for stimulating system immune responses and treatment are provided, including subcutaneous, intraperitoneal and intramuscular injections.Type: ApplicationFiled: February 8, 2021Publication date: April 6, 2023Applicant: RNAimmune, Inc.Inventors: Shenggao TANG, Dong SHEN, Chun LU, Ziyang HE, Jiaxi HE, Patrick Y. LU